Global Nitazoxanide Drug Market
Global Nitazoxanide Drug Market

Nitazoxanide Drug Comprehensive Study by Form (Tablet, Powder for Suspension), Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), Treatment (Diarrhea, Cryptosporidium parvum, Giardia duodenalis infections) Players and Region - Global Market Outlook to 2027

Nitazoxanide Drug Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Apr 2022 Edition 215 Pages 219 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Nitazoxanide Drug?
Antiprotozoal agents, such as nitazoxanide, are a type of drug. It works by preventing the spread of protozoa that cause diarrhoea. Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral medication used in medicine to treat helminthic, protozoal, and viral infections. It is sold under the brand names Alinia and others. It is used to treat infections caused by Cryptosporidium parvum and Giardia lamblia in immunocompetent people, and it has recently been repurposed to treat influenza.

The market study is broken down and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Nitazoxanide Drug market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis AG (Switzerland), AstraZeneca plc (United Kingdom), GlaxoSmithKline plc (United Kingdom), Bristol-Myers Squibb (United States), Mylan N.V. (United States), Johnson & Johnson (United States), Bayer AG (Germany), Merck & Co., Inc. (United States), Ranbaxy (India) and Amgen Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Nitazoxanide Drug market by Type, Application and Region.

On the basis of geography, the market of Nitazoxanide Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Form, the sub-segment i.e. Tablet will boost the Nitazoxanide Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital pharmacies will boost the Nitazoxanide Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment , the sub-segment i.e. Diarrhea will boost the Nitazoxanide Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.




Market Trend
  • Growing demand for Diarrhea disease capsules

Market Drivers
  • Rising Number of Diarrhea Diseases Patients.
  • Increasing pediatric population across the globe

Opportunities
  • Increasing Influence of Generic Drugs
  • Rising healthcare expenditure

Restraints
  • Patients Who Suffering from Diseases such as Asthma, Bronchitis, and Emphysema Should Not Take Nitazoxanide
  • Side Effects of Overdose.

Challenges
  • Infant risk when using this medication during breastfeeding


Key Target Audience
Pharmaceutical industries, Nitazoxanide Drug manufactures, Government & Regulatory Bodies, Hospitals and Carvedilol drug suppliers

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Novartis AG (Switzerland), AstraZeneca plc (United Kingdom), GlaxoSmithKline plc (United Kingdom), Bristol-Myers Squibb (United States), Mylan N.V. (United States), Johnson & Johnson (United States), Bayer AG (Germany), Merck & Co., Inc. (United States), Ranbaxy (India) and Amgen Inc. (United States) etc.

2. Can we have customized study for Nitazoxanide Drug Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Nitazoxanide Drug Market by 2027?
Analysts at AMA estimates Nitazoxanide Drug Market to reach USD Million by 2027.
Report Objectives / Segmentation Covered
By Form
  • Tablet
  • Powder for Suspension

By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Treatment
  • Diarrhea
  • Cryptosporidium parvum
  • Giardia duodenalis infections

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Diarrhea Diseases Patients.
      • 3.2.2. Increasing pediatric population across the globe
    • 3.3. Market Challenges
      • 3.3.1. Infant risk when using this medication during breastfeeding
    • 3.4. Market Trends
      • 3.4.1. Growing demand for Diarrhea disease capsules
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nitazoxanide Drug, by Form, Distribution Channel, Treatment and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Nitazoxanide Drug (Value)
      • 5.2.1. Global Nitazoxanide Drug by: Form (Value)
        • 5.2.1.1. Tablet
        • 5.2.1.2. Powder for Suspension
      • 5.2.2. Global Nitazoxanide Drug by: Distribution Channel (Value)
        • 5.2.2.1. Hospital pharmacies
        • 5.2.2.2. Retail pharmacies
        • 5.2.2.3. Online pharmacies
      • 5.2.3. Global Nitazoxanide Drug Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Nitazoxanide Drug (Price)
  • 6. Nitazoxanide Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol-Myers Squibb (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan N.V. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Ranbaxy (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amgen Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Nitazoxanide Drug Sale, by Form, Distribution Channel, Treatment and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Nitazoxanide Drug (Value)
      • 7.2.1. Global Nitazoxanide Drug by: Form (Value)
        • 7.2.1.1. Tablet
        • 7.2.1.2. Powder for Suspension
      • 7.2.2. Global Nitazoxanide Drug by: Distribution Channel (Value)
        • 7.2.2.1. Hospital pharmacies
        • 7.2.2.2. Retail pharmacies
        • 7.2.2.3. Online pharmacies
      • 7.2.3. Global Nitazoxanide Drug Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Nitazoxanide Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nitazoxanide Drug: by Form(USD Million)
  • Table 2. Nitazoxanide Drug Tablet , by Region USD Million (2016-2021)
  • Table 3. Nitazoxanide Drug Powder for Suspension , by Region USD Million (2016-2021)
  • Table 4. Nitazoxanide Drug: by Distribution Channel(USD Million)
  • Table 5. Nitazoxanide Drug Hospital pharmacies , by Region USD Million (2016-2021)
  • Table 6. Nitazoxanide Drug Retail pharmacies , by Region USD Million (2016-2021)
  • Table 7. Nitazoxanide Drug Online pharmacies , by Region USD Million (2016-2021)
  • Table 8. South America Nitazoxanide Drug, by Country USD Million (2016-2021)
  • Table 9. South America Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 10. South America Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 11. South America Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 12. Brazil Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 13. Brazil Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 14. Brazil Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 15. Argentina Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 16. Argentina Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 17. Argentina Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 18. Rest of South America Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 19. Rest of South America Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 20. Rest of South America Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 21. Asia Pacific Nitazoxanide Drug, by Country USD Million (2016-2021)
  • Table 22. Asia Pacific Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 23. Asia Pacific Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 24. Asia Pacific Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 25. China Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 26. China Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 27. China Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 28. Japan Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 29. Japan Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 30. Japan Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 31. India Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 32. India Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 33. India Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 34. South Korea Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 35. South Korea Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 36. South Korea Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 37. Australia Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 38. Australia Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 39. Australia Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 40. Rest of Asia-Pacific Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 41. Rest of Asia-Pacific Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 42. Rest of Asia-Pacific Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 43. Europe Nitazoxanide Drug, by Country USD Million (2016-2021)
  • Table 44. Europe Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 45. Europe Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 46. Europe Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 47. Germany Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 48. Germany Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 49. Germany Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 50. France Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 51. France Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 52. France Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 53. Italy Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 54. Italy Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 55. Italy Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 56. United Kingdom Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 57. United Kingdom Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 58. United Kingdom Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 59. Netherlands Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 60. Netherlands Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 61. Netherlands Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 62. Rest of Europe Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 63. Rest of Europe Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 64. Rest of Europe Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 65. MEA Nitazoxanide Drug, by Country USD Million (2016-2021)
  • Table 66. MEA Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 67. MEA Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 68. MEA Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 69. Middle East Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 70. Middle East Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 71. Middle East Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 72. Africa Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 73. Africa Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 74. Africa Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 75. North America Nitazoxanide Drug, by Country USD Million (2016-2021)
  • Table 76. North America Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 77. North America Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 78. North America Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 79. United States Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 80. United States Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 81. United States Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 82. Canada Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 83. Canada Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 84. Canada Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 85. Mexico Nitazoxanide Drug, by Form USD Million (2016-2021)
  • Table 86. Mexico Nitazoxanide Drug, by Distribution Channel USD Million (2016-2021)
  • Table 87. Mexico Nitazoxanide Drug, by Treatment USD Million (2016-2021)
  • Table 88. Company Basic Information, Sales Area and Its Competitors
  • Table 89. Company Basic Information, Sales Area and Its Competitors
  • Table 90. Company Basic Information, Sales Area and Its Competitors
  • Table 91. Company Basic Information, Sales Area and Its Competitors
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Nitazoxanide Drug: by Form(USD Million)
  • Table 99. Nitazoxanide Drug Tablet , by Region USD Million (2022-2027)
  • Table 100. Nitazoxanide Drug Powder for Suspension , by Region USD Million (2022-2027)
  • Table 101. Nitazoxanide Drug: by Distribution Channel(USD Million)
  • Table 102. Nitazoxanide Drug Hospital pharmacies , by Region USD Million (2022-2027)
  • Table 103. Nitazoxanide Drug Retail pharmacies , by Region USD Million (2022-2027)
  • Table 104. Nitazoxanide Drug Online pharmacies , by Region USD Million (2022-2027)
  • Table 105. South America Nitazoxanide Drug, by Country USD Million (2022-2027)
  • Table 106. South America Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 107. South America Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 108. South America Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 109. Brazil Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 110. Brazil Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 111. Brazil Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 112. Argentina Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 113. Argentina Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 114. Argentina Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 115. Rest of South America Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 116. Rest of South America Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 117. Rest of South America Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 118. Asia Pacific Nitazoxanide Drug, by Country USD Million (2022-2027)
  • Table 119. Asia Pacific Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 120. Asia Pacific Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 121. Asia Pacific Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 122. China Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 123. China Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 124. China Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 125. Japan Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 126. Japan Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 127. Japan Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 128. India Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 129. India Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 130. India Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 131. South Korea Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 132. South Korea Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 133. South Korea Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 134. Australia Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 135. Australia Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 136. Australia Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 137. Rest of Asia-Pacific Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 138. Rest of Asia-Pacific Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 139. Rest of Asia-Pacific Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 140. Europe Nitazoxanide Drug, by Country USD Million (2022-2027)
  • Table 141. Europe Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 142. Europe Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 143. Europe Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 144. Germany Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 145. Germany Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 146. Germany Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 147. France Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 148. France Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 149. France Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 150. Italy Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 151. Italy Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 152. Italy Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 153. United Kingdom Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 154. United Kingdom Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 155. United Kingdom Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 156. Netherlands Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 157. Netherlands Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 158. Netherlands Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 159. Rest of Europe Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 160. Rest of Europe Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 161. Rest of Europe Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 162. MEA Nitazoxanide Drug, by Country USD Million (2022-2027)
  • Table 163. MEA Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 164. MEA Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 165. MEA Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 166. Middle East Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 167. Middle East Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 168. Middle East Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 169. Africa Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 170. Africa Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 171. Africa Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 172. North America Nitazoxanide Drug, by Country USD Million (2022-2027)
  • Table 173. North America Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 174. North America Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 175. North America Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 176. United States Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 177. United States Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 178. United States Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 179. Canada Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 180. Canada Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 181. Canada Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 182. Mexico Nitazoxanide Drug, by Form USD Million (2022-2027)
  • Table 183. Mexico Nitazoxanide Drug, by Distribution Channel USD Million (2022-2027)
  • Table 184. Mexico Nitazoxanide Drug, by Treatment USD Million (2022-2027)
  • Table 185. Research Programs/Design for This Report
  • Table 186. Key Data Information from Secondary Sources
  • Table 187. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nitazoxanide Drug: by Form USD Million (2016-2021)
  • Figure 5. Global Nitazoxanide Drug: by Distribution Channel USD Million (2016-2021)
  • Figure 6. South America Nitazoxanide Drug Share (%), by Country
  • Figure 7. Asia Pacific Nitazoxanide Drug Share (%), by Country
  • Figure 8. Europe Nitazoxanide Drug Share (%), by Country
  • Figure 9. MEA Nitazoxanide Drug Share (%), by Country
  • Figure 10. North America Nitazoxanide Drug Share (%), by Country
  • Figure 11. Global Nitazoxanide Drug share by Players 2021 (%)
  • Figure 12. Global Nitazoxanide Drug share by Players (Top 3) 2021(%)
  • Figure 13. Global Nitazoxanide Drug share by Players (Top 5) 2021(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 17. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. AstraZeneca plc (United Kingdom) Revenue: by Geography 2021
  • Figure 19. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2021
  • Figure 21. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bristol-Myers Squibb (United States) Revenue: by Geography 2021
  • Figure 23. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Mylan N.V. (United States) Revenue: by Geography 2021
  • Figure 25. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 26. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 27. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 29. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co., Inc. (United States) Revenue: by Geography 2021
  • Figure 31. Ranbaxy (India) Revenue, Net Income and Gross profit
  • Figure 32. Ranbaxy (India) Revenue: by Geography 2021
  • Figure 33. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Amgen Inc. (United States) Revenue: by Geography 2021
  • Figure 35. Global Nitazoxanide Drug: by Form USD Million (2022-2027)
  • Figure 36. Global Nitazoxanide Drug: by Distribution Channel USD Million (2022-2027)
  • Figure 37. South America Nitazoxanide Drug Share (%), by Country
  • Figure 38. Asia Pacific Nitazoxanide Drug Share (%), by Country
  • Figure 39. Europe Nitazoxanide Drug Share (%), by Country
  • Figure 40. MEA Nitazoxanide Drug Share (%), by Country
  • Figure 41. North America Nitazoxanide Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Novartis AG (Switzerland)
  • AstraZeneca plc (United Kingdom)
  • GlaxoSmithKline plc (United Kingdom)
  • Bristol-Myers Squibb (United States)
  • Mylan N.V. (United States)
  • Johnson & Johnson (United States)
  • Bayer AG (Germany)
  • Merck & Co., Inc. (United States)
  • Ranbaxy (India)
  • Amgen Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation